当前位置: X-MOL 学术J. Immunol. Methods › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A cell-based immunogenicity assay to detect antibodies against chimeric antigen receptor expressed by tisagenlecleucel.
Journal of Immunological Methods ( IF 1.6 ) Pub Date : 2019-11-01 , DOI: 10.1016/j.jim.2019.112692
Bernd Potthoff 1 , Fraser McBlane 1 , Sebastian Spindeldreher 2 , Denise Sickert 3
Affiliation  

The use of T-cells expressing Chimeric Antigen Receptors (CARs) offers new opportunities for cancer treatment, as well as new challenges for the bioanalysis of this new class of drugs. The analysis of humoral immunogenicity (anti-drug antibodies) against CARs could be performed with a bridging ELISA, using labeled CAR fragments. However, outside of its native cell membrane environment and without potential interaction partners on the cell surface, a labeled or coated recombinant CAR fragment may structurally differ from the membrane-bound CAR expressed on CAR-T cells. Consequently, immunogenicity to CARs may be missed due to the artificial nature of a ligand binding assay setup. T-cell lines expressing the CAR offer the opportunity to measure anti-drug antibodies to the CAR in its natural cell environment, as an alternative to ligand-binding assays. Here we describe a novel, flow cytometry-based humoral immunogenicity assay for tisagenlecleucel (CTL019, Kymriah®) using a human T-cell line that expresses murine CAR19. The assay described here was fully validated according to health authority guidelines for the development and validation of immunogenicity assays and has a sensitivity of 100 ng/mL. A good correlation of screening assay signal strengths to titer assay results was observed while exploring options to increase titration assay throughput. Pre-existing antibodies against the cell line used in the assay as well as against the CAR itself complicate the assay and data interpretation.

中文翻译:

一种基于细胞的免疫原性检测试剂盒,用于检测针对三苯三氮杂萘表达的嵌合抗原受体的抗体。

表达嵌合抗原受体(CAR)的T细胞的使用为癌症治疗提供了新的机遇,也为这种新型药物的生物分析带来了新的挑战。可以使用标记的CAR片段,通过桥接ELISA分析针对CAR的体液免疫原性(抗药物抗体)。然而,在其天然细胞膜环境之外且在细胞表面上没有潜在的相互作用伴侣,标记或包被的重组CAR片段在结构上可能与在CAR-T细胞上表达的膜结合CAR不同。因此,由于配体结合测定装置的人工性质,可能会错过对CAR的免疫原性。表达CAR的T细胞系提供了在其天然细胞环境中测量抗CAR药物的机会,作为配体结合测定的替代方法。在这里,我们描述了一种新颖的,基于流式细胞仪的体液免疫原性测定法,用于表达tisagenlecleucel(CTL019,Kymriah®),使用表达鼠类CAR19的人类T细胞系。根据卫生权威指南对此处所述的测定方法进行了充分验证,以开发和验证免疫原性测定方法,其灵敏度为100 ng / mL。在探索增加滴定分析通量的方法时,观察到筛选分析信号强度与滴度分析结果之间具有良好的相关性。针对测定中使用的细胞系以及CAR本身的预先存在的抗体使测定和数据解释变得复杂。使用表达鼠CAR19的人类T细胞系。根据卫生权威指南对此处所述的测定方法进行了充分验证,以开发和验证免疫原性测定方法,其灵敏度为100 ng / mL。在探索增加滴定分析通量的方法时,观察到筛选分析信号强度与滴定分析结果之间的良好相关性。针对测定中使用的细胞系以及CAR本身的预先存在的抗体使测定和数据解释变得复杂。使用表达鼠CAR19的人类T细胞系。根据卫生权威指南对此处所述的测定方法进行了充分验证,以开发和验证免疫原性测定方法,灵敏度为100 ng / mL。在探索增加滴定分析通量的方法时,观察到筛选分析信号强度与滴定分析结果之间的良好相关性。针对检测中使用的细胞系以及CAR本身的预先存在的抗体使检测和数据解释变得复杂。在探索增加滴定分析通量的方法时,观察到筛选分析信号强度与滴度分析结果之间具有良好的相关性。针对检测中使用的细胞系以及CAR本身的预先存在的抗体使检测和数据解释变得复杂。在探索增加滴定分析通量的方法时,观察到筛选分析信号强度与滴定分析结果之间的良好相关性。针对检测中使用的细胞系以及CAR本身的预先存在的抗体使检测和数据解释变得复杂。
更新日期:2019-11-01
down
wechat
bug